Valeant Pharmaceuticals entered into a licensing agreement with Norgine for a bowel-cleansing oral solution used to prepare for colonoscopies.
EndoChoice reported total revenue for the second quarter of 2016 was $19.3 million, but net loss for the second quarter totaled $24.7 million.
EndoChoice’s Lumos received FDA clearance and was recently launched in the United States.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: Aug. 1 — Aug. 5
EndoChoice launches the Lumos imaging software system: 4 takeaways
Dr. Farzana Rashid Hossain appointed to 1st Philadelphia Commission for Women — 4 thoughts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
